Consistently, clinical database analysis revealed a poor survival outcome for cancer patients with high integrin β3 mRNA expression, suggesting that the integrin β3-Akt-GSK3β signaling axis could be used as an important therapeutic target for preventing malignant cancer progression. The gene discussed is GSK3B; the disease is cancer.